Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 45 AND POTASSIUM CHLORIDE 0 22 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 45 AND POTASSIUM CHLORIDE 0 22 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE.
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose provides caloric support and prevents ketosis; sodium chloride maintains electrolyte balance; potassium chloride replaces potassium losses and restores intracellular potassium levels.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Intravenous infusion. Dose determined by fluid, electrolyte, and caloric requirements. Typical adult maintenance: 100-200 mL/hour (2-4 L/day) of D5 0.45% NaCl with 20 mEq/L KCl. Rate adjusted based on serum potassium and fluid status.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Dextrose: plasma half-life approximately 20-30 minutes; prolonged in renal impairment or diabetes. Potassium: terminal half-life ~8 hours (intracellular equilibration); clinical context: hypokalemia correction requires monitoring.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Dextrose: primarily metabolized to CO2 and water; <5% excreted unchanged in urine. Sodium, chloride, and potassium: primarily excreted renally (90%+); small fecal/biliary loss.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte